Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.43 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405458 | 0.90 | HCRTR1 (0.44) | HCRTR1HCRTR2OXTRAVPR1AWDR5 | |
| SCHEMBL1972060 | 0.89 | HCRTR1 (0.44) | HCRTR1HCRTR2OXTRAVPR1AWDR5 | |
| SCHEMBL1967032 | 0.89 | HCRTR1 (0.46) | HCRTR1HCRTR2OXTR | |
| SCHEMBL2407371 | 0.88 | HCRTR1 (0.42) | HCRTR1HCRTR2OXTRAVPR1A | |
| SCHEMBL1969612 | 0.88 | HCRTR1 (0.42) | HCRTR1HCRTR2OXTRAVPR1AWDR5 | |
| SCHEMBL2408535 | 0.88 | HCRTR2 (0.43) | HCRTR1HCRTR2OXTRAVPR1AWDR5 | |
| SCHEMBL2405462 | 0.86 | HCRTR1 (0.47) | HCRTR1HCRTR2OXTRAVPR1AWDR5 | |
| SCHEMBL2406276 | 0.86 | HCRTR1 (0.43) | HCRTR1HCRTR2OXTRAVPR1A | |
| SCHEMBL1970052 | 0.86 | HCRTR1 (0.48) | HCRTR1HCRTR2OXTRAVPR1A | |
| SCHEMBL1969001 | 0.86 | HCRTR1 (0.41) | HCRTR1HCRTR2OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885OXTR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.